# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sir John Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX005-SYN-TD
- Date: 1845-01-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashby-Nwankwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of home blood pressure readings, seen the same day by wilderness and expedition medicine. **S**

## History of present illness

Sir John returns with a week of home readings, taken morning and evening with a validated upper-arm monitor and a large cuff: the average of 28 readings is 144/90, with no reading below 132/84. He has cut his wine to one glass with dinner and his salt, and walks every day. He has no headaches, chest pain, breathlessness, palpitations or ankle swelling. He brought no urine sample to the intake visit and has not yet given one. The tuberculosis blood test drawn at intake is negative. He is seen this afternoon by Dr. Okafor-Lindqvist of wilderness and expedition medicine. **S**

| Element | Detail |
|---|---|
| Home readings | Seven-day average 144/90 mmHg (28 readings) |
| Office reading | 148/92 mmHg |
| Symptoms | None |
| Lifestyle | One glass of wine with dinner; less salt; daily walks |
| Tuberculosis blood test | Negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No breathlessness |
| Neurological | Negative | No headache or visual change |
| Psychiatric | Negative | Mood good; looking forward to the command |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet once daily **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/92 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 90.4 kg; BMI 31.3 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/92, pulse 76; weight 90.4 kg, BMI 31.3; waist 106 cm |
| Eyes | Fundi: no arteriovenous nicking, hemorrhages or exudates |
| Cardiovascular | Regular rhythm; no murmur or gallop; no carotid or abdominal bruit; foot pulses present; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension, stage 2** (I10). Home average 144/90 confirms stage 2 hypertension. No target-organ damage on the ECG or fundi; kidney function normal. PREVENT 10-year cardiovascular risk about 6 percent and Pooled Cohort Equations about 8 percent. Under the 1844 guideline, stage 2 hypertension calls for medicine with lifestyle change, with a goal below 130/80. With Dr. Okafor-Lindqvist he chose amlodipine, which needs no laboratory monitoring and does not cause low sodium or kidney injury with the dehydration and cold diuresis of polar travel. A statin was discussed at a borderline risk; he chose lifestyle change for now. **S**
   - Amlodipine 5 mg every morning from today.
   - Home readings twice a day for a week before the four-week review, then weekly.
   - Echocardiogram for stage 2 hypertension.
   - Urine albumin-to-creatinine ratio, missed at intake, at the next visit.
2. **Obesity, class 1** (E66.811). He wants to lose about 5 percent of his weight before sailing, by walking, hill work and smaller portions; no weight-loss medicine before departure. **S**
   - His own plan, reviewed at each visit.
3. **Vitamin D insufficiency** (E55.9). 25-hydroxyvitamin D 22 ng/mL in midwinter, with years of polar darkness ahead. **S**
   - Vitamin D3 25 micrograms (1,000 units) daily from today and through the expedition; recheck before departure.
4. **Expedition preparation** (Z71.84). Dr. Okafor-Lindqvist finds no barrier to the command so far and advises cardiac testing, a nutrition and food-safety plan, cold-injury training, vaccinations and an evacuation plan. **S**
   - Exercise treadmill test in about four weeks.
   - Vaccinations and dental check at the preventive visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, large cuff, average of two readings) | Every visit | Completed today | 148/92 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and two to four weeks after each treatment change, then weekly | Completed today | Seven-day average 144/90 mmHg confirms stage 2 hypertension; repeat a week before the next visit |
| Examination | Weight, BMI and waist | Every visit | Completed today | 90.4 kg, BMI 31.3, waist 106 cm |
| Examination | Cardiac auscultation | Every visit | Completed today | No murmur or gallop |
| Examination | Fundoscopic examination | Yearly | Completed today | No hypertensive retinopathy |
| Laboratory | Basic metabolic panel, potassium and eGFR | Yearly (every six months only on a diuretic or renin-angiotensin blocker) | Up to date | Normal at intake: sodium 140, potassium 4.2, creatinine 0.98 mg/dL, eGFR 88 |
| Laboratory | Lipid panel | Yearly | Up to date | At intake: total cholesterol 188, HDL 52, LDL 112, triglycerides 120 mg/dL |
| Laboratory | HbA1c or fasting glucose | Yearly | Up to date | HbA1c 5.6% at intake |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Deferred | The urine sample planned at intake was not collected, and none was given today. Without it, early kidney damage cannot be excluded, but creatinine, eGFR and the fundi are normal, so no harm is likely in the next few weeks. Corrective action: a urine cup given today and a standing order for the next visit |
| Laboratory | TSH | At diagnosis | Up to date | 1.9 mIU/L at intake |
| Imaging | 12-lead ECG | At diagnosis | Up to date | Normal at intake; no left ventricular hypertrophy |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected left ventricular hypertrophy | Ordered | Booked before the four-week review |
| Imaging | Renal ultrasound or renal artery imaging | Only for resistant hypertension or a suspected secondary cause | Not indicated | No features of a secondary cause; potassium normal |
| Examination | Ankle-brachial index | Every two to three years from 65 or with a smoking history | Not indicated | Age 58 and never smoked; foot pulses present |
| Survey | Cardiovascular risk (PREVENT and Pooled Cohort Equations) | Yearly | Completed today | PREVENT about 6 percent; Pooled Cohort Equations about 8 percent; statin declined for now |
| Survey | PHQ-9 depression screen | Yearly | Up to date | PHQ-9 3 at intake, item 9 scored 0 |
| Medication safety | Amlodipine safety: ankle swelling, dizziness, flushing | When started and at each visit | Completed today | Started today; told to report ankle swelling or dizziness |
| Referral | Wilderness and expedition medicine consultation | Before clearance for remote duty | Completed today | Seen by Dr. Okafor-Lindqvist today |
| Examination | Exercise treadmill test before strenuous remote work | Before clearance | Ordered | Booked in four weeks |
| Self-management | Nutrition and food safety for the expedition (vitamin C and D, rations, cans, lead, botulism) | Before departure | Completed today | Vitamin D3 started; vitamin C plan and food-safety advice given |

## Goal progress

- Confirm or exclude hypertension with a week of home readings. Outcome by 1845-01-27: Home average 144/90 mmHg: stage 2 hypertension confirmed. **S**
- Blood pressure below 130/80 mmHg at home before departure. In progress; target 1845-04-07. **S**
- Lose about 5 percent of body weight before sailing by his own plan of walking, hill work and smaller portions. In progress; target 1845-05-05. **S**
- Medical clearance for the command with a written expedition health plan, medical kit and evacuation plan. In progress; target 1845-05-05. **S**

## Medication changes

- Started: Amlodipine 5 mg oral tablet once daily **S**
- Started: Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, hypertension and hyperlipidemia monographs (2026), Aether Forge
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (2024), Wilderness Medical Society (Wilderness Environ Med 2024;35(2):183-197)
- Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recomm Rep 2021;70(2):1-30)
- Recommendations for medical management of adult lead exposure (2007), Kosnett MJ, et al. (Environ Health Perspect 2007;115(3):463-471)
- Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force

## Follow-up

- Echocardiogram and urine sample before the four-week review. Home readings for a week before then. Call for chest pain, breathlessness, fainting or ankle swelling. **S**
- Next scheduled visit 1845-02-24: four-week review after starting amlodipine: blood pressure, side effects, echocardiogram and urine albumin. **S**
